AusBiotech is honoured to announce the establishment of the Depaz Oration, an annual keynote to be introduced at the AusBiotech Conference in 2025 in ...

The company is banking on revenue from its Sanofi deal and vaccines in development ... Trump as U.S. president will be a boon ...

Sanofi will take the lead co-commercialization role for our ... The trial will enroll adults aged 65 years and older and is ...

By using automated content recognition, Beatgrid can measure cross-platfrom ad exposure by individual as well as the ...

With multiple drugmakers already announcing a slew of radiopharmaceutical moves this year, France’s Orano Med is doubling ...

The S&P 500 fell 1.3 per cent on Friday, bringing its losses for the week to 2.1 per cent, its steepest drop since early September. The Nasdaq Composite fell 2.2 per cent on Friday and 3.1 per cent ...

The accuracy of skin cancer diagnosis varied by lesion type, physician specialty and experience, and examination method, with ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

The PEGylated Proteins Market is primarily driven by the growing demand for effective drug delivery systems, particularly in the treatment of chronic diseases such as cancer, hepatitis, and rheumatoid ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...